PDE10A and schizophrenia: Selective PDE10A inhibitors represent a potentially new strategy in the treatment of schizophrenia, with preliminary evidence supporting a favorable safety and tolerability profile, and preclinical studies suggest PDE-10A inhibitors may have the potential for efficacy across multiple symptom domains (Grauer et al. 2009; Kehler and Nielsen 2011; Suzuki et al. 2015).